InMed Pharmaceuticals
8 hedge funds and large institutions have $18.6K invested in InMed Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 2 closing their positions.
28% more capital invested
Capital invested by funds: $14.5K → $18.6K (+$4.04K)
0.02% more ownership
Funds ownership: 0.02% → 0.04% (+0.02%)
11% less funds holding
Funds holding: 9 → 8 (-1)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.8K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$55 |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$18 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$1.7K |
| 2 |
BlackRock
New York
|
-$46 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $18.3K | +$11.8K | +645 | +94% |
|
|
TWC
2
TD Waterhouse Canada
Toronto,
Ontario, Canada
| $76 | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $48 | +$55 | +3 | New |
|
|
4
Osaic Holdings
Scottsdale,
Arizona
| $40 | +$18 | +1 | +50% |
|
|
AWM
5
AllSquare Wealth Management
Albany,
New York
| $14 | – | – | – |
|
|
FDCDDQ
6
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $13 | – | – | – |
|
7
National Bank of Canada
Montreal,
Quebec, Canada
| $13 | – | – | – |
|
|
GCM
8
Gables Capital Management
Miami,
Florida
| $1 | – | – | – |
|
9
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| $1 | – | – | – |
|
|
10
Bank of America
Charlotte,
North Carolina
| – | -$1.7K | -92 | Closed |
|
|
11
BlackRock
New York
| – | -$46 | -3 | Closed |
|
INM Hedge Fund Activity: Q3 2023 in Review
8 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in InMed Pharmaceuticals (INM) for Q3 2023, worth a combined $18.6K — up 28% from $14.5K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of INM and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.
The largest buyer was Susquehanna International Group, adding an estimated $11.8K. The largest seller was Bank of America, exiting entirely with an estimated $1.7K sold.
- 8 institutional investors held InMed Pharmaceuticals (INM) as of Q3 2023, down from 9 in Q2 2023.
- Funds reported $18.6K of InMed Pharmaceuticals stock for Q3 2023, up 28% quarter-over-quarter.
- 1 fund opened new InMed Pharmaceuticals positions in Q3 2023 and 2 closed out, a net change of -1 holder.
- The largest InMed Pharmaceuticals buyer in Q3 2023 was Susquehanna International Group, an estimated $11.8K added.
- The largest InMed Pharmaceuticals seller in Q3 2023 was Bank of America, an estimated $1.7K sold.
Based on aggregated 13F filings for Q3 2023.